|Videos|December 9, 2017

About 1200 Suicides in the US Each Year Result from Lyme & Associated Diseases

Robert Bransfield, MD, DLFAPA, discusses direct methods that can be used to acquire statistics related to suicides that are a result of Lyme and associated diseases.

Robert Bransfield, MD, DLFAPA, private practice, Psychiatry, in Red Bank, New Jersey, discusses direct methods that can be used to acquire statistics related to suicides that are a result of Lyme and associated diseases.

Interview Transcript (modified slightly for readability):

“When we look for trying to acquire direct methods, there’s a quote by Yogi Berra, and Yogi Berra said, ‘I would never have seen it if I didn’t believe it.’ So, we never look for it when someone dies from suicide; we need to look for it when someone dies from suicide. Was there a history of Lyme disease? Are there physiological indications in the blood or brain tissue or in the body that would suggest the presence of tick-borne disease? Once we look for that, I think we would see a stronger correlation, but because we have never looked at that, we can’t say what the exact statistics are.

When you look at the ratios of how many people are suicidal, one way to calculate it is, how many cases of Lyme are there? How many cases become persistent with persistent symptoms? What percent of those people have suicidal thoughts? And then we look at what percent of people with suicidal thoughts actually commit suicide.

And so, when you figure out those statistics, even using the most conservative statistics, it works out that there are probably 1200 suicides per year in the United States as a result of Lyme and associated diseases, and that’s a very significant number of people. And it would be very good to prevent those suicides if we could in any way do that.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.